Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Inovio Pharmaceuticals, Inc. - Common Stock (NQ:INO)

1.990 -0.140 (-6.57%)
Streaming Delayed Price Updated: 11:40 AM EDT, May 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Inovio Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
10 Biggest Price Target Changes For Friday
Barclays cut Netflix, Inc. (NASDAQ: NFLX) price target from $675 to $425. Netflix shares fell 19.6% to $408.58 in pre-market trading. Keybanc cut Chipotle Mexican Grill, Inc... 
Via Benzinga
Growing Acceptance Of Digital Health Services is a Huge Boon for Healthcare Cloud Computing Market
Palm Beach, FL – January 20, 2022 – FinancialNewsMedia.com News Commentary – Cloud computing increases real-time data collection and improves accessibility to the data. It has outpaced the conventional... 
Via FinancialNewsMedia
Bill Gates Says Misinformation Related To Fauci, Himself Doesn't 'Make Sense,' Talks COVID-19 After Omicron
Microsoft Corporation (NASDAQ: MSFT) co-founder Bill Gates answered questions related to COVID-19 on Twitter Tuesday. What Happened: The questions to Gates were routed through... 
Via Benzinga
Stocks Hitting New 52-Week Lows Today
On Monday morning, 60 companies achieved new lows for the year. Points of Interest From Today's 52-Week Lows And Highs: Ginkgo Bioworks Holdings (NYSE:DNA) was... 
Via Benzinga
Wingstop, Akamai Initiations Among Today's Top Calls On Wall Street
Benchmark analyst Todd Brooks initiated coverage of Wingstop (WING) with a Hold rating and no price target. The analyst believes the stock's risk/reward is balanced at these levels given the current 
Via Talk Markets
If You Invested $1,000 In Inovio Stock One Year Ago, Here's How Much You'd Have Now
Investors who have owned stocks in the last year have generally experienced some big gains. In fact, the SPDR S&P 500 (NYSE: SPY) total return over the last 12 months is 29.2... 
Via Benzinga
Market Briefing For Thursday, Dec. 23
'Fortune favors the brave' it is said; it's partially so in this market, where we certainly got the ignition Tuesday of the seasonal rebound we looked for and more on Wednesday. 
Via Talk Markets
Why Jim Cramer Likes MGM Growth Properties
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Enterprise Products Partners L.P. (NYSE: 
Via Benzinga
Why You Should Buy Moderna Stock at Every Dip
Moderna’s cash growth will continue as demand for booster shots and vaccines for the omicron variant increase, giving a boost to MRNA stock. 
Via InvestorPlace
Exposures COVID-19
Here's Why These 3 COVID-19 Vaccine Stocks Got Crushed This Week
These second-tier COVID-19 vaccine players plunged due to fears about the potential impacts of the omicron variant. 
Via The Motley Fool
Exposures COVID-19
The 'Highly Mutated Virus' Signals A Need For Annual Shots: BioNTech CEO
The omicron variant signals a need for annual Covid shots, BioNTech's CEO said. 
Via Investor's Business Daily
2 Stocks That Are Down 60% (or More) From Their 52-Week Highs
One of these stocks is poised to rebound, but the other still looks very risky. 
Via The Motley Fool
Topics Economy
Exposures COVID-19 Economy
Adagio Continues Its Run As Biotech Stocks Moderna, BioNTech Dive On Omicron Threat
Biotech stocks diverged Tuesday with Adagio continuing a run on the potential for its antibody to target Covid's omicron variant. 
Via Investor's Business Daily
Vaccine Stocks Ask The Unthinkable: What Happens If Today's Covid Shots Fail?
Smaller companies are working on next-generation approaches to Covid treatment. 
Via Investor's Business Daily
20 Stocks Moving in Monday's Pre-Market Session
Gainers Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) rose 85.6% to $3.88 in pre-market trading after jumping 14% on Friday. Petros Pharmaceuticals recently said Q3 sales results... 
Via Benzinga
Novavax Working On New COVID-19 Vaccine To Combat Omicron Variant
Novavax Inc (NASDAQ: NVAX) said it had started working on a version of its COVID-19 vaccine to target the variant detected in South Africa. It said that the shot would be... 
Via Benzinga
Exposures COVID-19
Battle of the COVID Vaccine Contenders: Inovio vs. Ocugen
Both vaccine makers still have big hurdles to jump. 
Via The Motley Fool
Exposures COVID-19
Does This News Make Inovio Pharmaceuticals Stock a Buy?
The company is closer than ever to launching its coronavirus vaccine -- but will it be good enough to make the stock worth purchasing? 
Via The Motley Fool
Exposures COVID-19
Why Inovio Stock Is Rising Today
The company received a green light to begin a U.S. phase 3 study of its COVID-19 vaccine candidate. 
Via The Motley Fool
Exposures COVID-19 Product Safety
Inovio Pharmaceuticals (INO) Q3 2021 Earnings Call Transcript
INO earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Inovio Pharmaceuticals Sees A Bounce Off Support After COVID-19 Vaccine News
Inovio Pharmaceuticals Inc. (NASDAQ: INO) shares are trading higher Tuesday after the FDA removed a hold on the company’s late-stage COVID-19 vaccine trial in the U.S.... 
Via Benzinga
Exposures COVID-19 Product Safety
Why Shares of Inovio Pharmaceuticals Rallied Today
The FDA lifted its hold on the next step of its COVID-19 vaccine trial, although that doesn't mean much at this point. 
Via The Motley Fool
Exposures COVID-19 Product Safety
RBLX Stock Alert: What Is Going on With Roblox Shares Today?
Roblox (RBLX) stock is soaring higher on Tuesday following the release of the company's earnings report for the third quarter of 2021. 
Via InvestorPlace
INO Stock: The Covid-19 Vaccine News Helping Inovio Power Higher
Inovio Pharmaceuticals (INO) stock is pushing higher on Tuesday after providing investors with an update on its Covid-19 vaccine. 
Via InvestorPlace
Exposures COVID-19
FDA Lifts Clinical Hold On Inovio's COVID-19 Vaccine Trial
The FDA has lifted a partial clinical hold on a late-stage trial of Inovio Pharmaceuticals Inc's (NASDAQ: INO) COVID-19 vaccine in the U.S. Inovio said it... 
Via Benzinga
Exposures COVID-19 Product Safety
Rising Test Accuracy Standards Needed as On-Site Demand for Covid-19 Testing Increases
FN Media Group Presents USA News Group News Commentary Vancouver, BC –November 9, 2021 – USA News Group – After the launch of US President Joe Biden’s pushing of mandatory vaccination/testing in the... 
Via FinancialNewsMedia
Exposures COVID-19
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Compass Pathways (NASDAQ:CMPS) shares rose 18.43% to $51.0 during Tuesday's pre-market session. The company's market cap stands at $2.1 billion. As per the... 
Via Benzinga
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces... 
Via Benzinga
AstraZeneca's Medimmune Terminates DNA Cancer Vaccine Program With Inovio
MedImmune Limited, a unit of AstraZeneca Plc (NASDAQ: AZN), has notified Inovio Pharmaceuticals Inc (NASDAQ: INO) to terminate the DNA cancer vaccine... 
Via Benzinga
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.